PMID- 29553070
OWN - NLM
STAT- MEDLINE
DCOM- 20180905
LR  - 20180905
IS  - 0387-821X (Print)
IS  - 0387-821X (Linking)
VI  - 40
IP  - 1
DP  - 2018
TI  - Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl 
      Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and 
      Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
PG  - 1-9
LID - 10.7888/juoeh.40.1 [doi]
AB  - Our purpose was to determine the effects of teneligliptin and sitagliptin, two 
      dipeptidyl peptidase 4 inhibitors (DPP4-Is) with different half-lives, on 
      glycemic variability and glucagon-like peptide-1 (GLP-1) levels in Japanese 
      patients with type 2 diabetes mellitus (T2DM). The study subjects were 14 
      drug-naive patients with T2DM who were allocated to either a 20 mg/day 
      teneligliptin group (n = 7) or a 50 mg/day sitagliptin group (n = 7) for 7 days, 
      then switched to the other treatment for another 7 days. Meal tolerance tests 
      were performed at the time of no treatment, and after treatment with each DPP4-Is 
      at supper. We evaluated the effects of each drug on glucose fluctuation using 
      continuous glucose monitoring (CGM). There was no significant difference between 
      the two groups in the primary endpoint (maximum glucose level after supper), nor 
      in the secondary endpoint: area under the curve (AUC) for plasma glucose (>/=140 
      mg/dl) after supper (18:00 - 24:00). Teneligliptin significantly improved the AUC 
      for plasma glucose (>/=140 mg/dl) after supper (20:00-24:00) (P = 0.048), and also 
      significantly increased the GLP-1 level at 30 minutes after the meal load (P = 
      0.030). No serious adverse effects were noted in either group, apart from a few 
      episodes of asymptomatic hypoglycemia. A daily dose of teneligliptin improved the 
      AUC for plasma glucose at 20:00 to 24:00 (>/=140 mg/dl) after the meal tolerance 
      test, and also significantly increased the levels of activated GLP-1 after the 
      test meal.
FAU - Kurozumi, Akira
AU  - Kurozumi A
AD  - First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Japan.
FAU - Okada, Yosuke
AU  - Okada Y
AD  - First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Japan.
FAU - Sugai, Kei
AU  - Sugai K
AD  - First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Japan.
FAU - Torimoto, Keiichi
AU  - Torimoto K
AD  - First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Japan.
FAU - Tanaka, Yoshiya
AU  - Tanaka Y
AD  - First Department of Internal Medicine, School of Medicine, University of 
      Occupational and Environmental Health, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - J UOEH
JT  - Journal of UOEH
JID - 7909645
RN  - 0 
      (3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Thiazolidines)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/*analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Glucagon-Like Peptide 1/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrazoles/*therapeutic use
MH  - Sitagliptin Phosphate/*therapeutic use
MH  - Thiazolidines/*therapeutic use
OTO - NOTNLM
OT  - continuous glucose monitoring
OT  - dipeptidyl peptidase 4 inhibitors
OT  - glucagon like peptide-1
EDAT- 2018/03/20 06:00
MHDA- 2018/09/06 06:00
CRDT- 2018/03/20 06:00
PHST- 2018/03/20 06:00 [entrez]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2018/09/06 06:00 [medline]
AID - 10.7888/juoeh.40.1 [doi]
PST - ppublish
SO  - J UOEH. 2018;40(1):1-9. doi: 10.7888/juoeh.40.1.